Predictive and prognostic biomarkers can be an appealing strategy to stratify patients that are likely to benefit from treatment. Our non-invasive biomarkers can do exactly that, and much more. Furthermore, we have a novel serum biomarker for calprotectin, which is extremely popular for clinical programs in inflammatory bowel diseases such as UC and Crohns.
More about our biomarkers for IBD
Search and find publications that we have published.
Please don't hesitate to contact us if you have any questions or other inquiries.
We use cookies on our site to enable essential services and functionalities, and collect data in regards to visitor information to provide the best possible experience. By using our website, you agree to our Privacy Policy and our cookies usage. Cookie Policy Privacy Statement
